A+AVD versus eBEACOPP in advanced-stage Hodgkin lymphoma

Affiliations

Comment

Louis F Diehl. Lancet Haematol. 2021 Jun.

. 2021 Jun;8(6):e384-e386.

doi: 10.1016/S2352-3026(21)00129-0.

¹ Duke University Medical Center, Durham, NC 27705, USA. Electronic address: diehl005@mc.duke.edu.

No abstract available

Conflict of interest statement

I declare no competing interests.

Brentuximab vedotin with chemotherapy for stage III or IV classical Hodgkin lymphoma (ECHELON-1): 5-year update of an international, open-label, randomised, phase 3 trial.
Straus DJ, Długosz-Danecka M, Connors JM, Alekseev S, Illés Á, Picardi M, Lech-Maranda E, Feldman T, Smolewski P, Savage KJ, Bartlett NL, Walewski J, Ramchandren R, Zinzani PL, Hutchings M, Munoz J, Lee HJ, Kim WS, Advani R, Ansell SM, Younes A, Gallamini A, Liu R, Little M, Fenton K, Fanale M, Radford J. Straus DJ, et al. Lancet Haematol. 2021 Jun;8(6):e410-e421. doi: 10.1016/S2352-3026(21)00102-2. Lancet Haematol. 2021. PMID: 34048680 Clinical Trial.